Biodesix Inc (BDSX): Long-Term Debt

Annual figures by period end, from SEC filings.

$50.01M
As of 2025-12-31
$50.00M
As of 2026-06-30
+18.4%
3-year compound annual growth
+12.2%
5-year compound annual growth
2020-12-31: $28.08M2021-12-31: $10.07M2022-12-31: $30.13M2023-12-31: $40.08M2024-12-31: $40.03M2025-12-31: $50.01M$50.01M
2020-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$50.01M+24.9%2026-02-26, Balance as of period end
2024-12-31$40.03M-0.1%2025-03-03, Balance as of period end
2023-12-31$40.08M+33.0%2024-03-01, Balance as of period end
2022-12-31$30.13M+199.0%2023-03-06, Balance as of period end
2021-12-31$10.07M-64.1%2022-03-14, Balance as of period end
2020-12-31$28.08Mn/a2021-03-16, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Biodesix Inc (BDSX)2025-12-31$50.01M+24.9%
Exagen Inc. (XGN)2025-12-31$22.91M+13.1%
American Shared Hospital Services (AMS)2025-12-31$17.40M-14.8%
BillionToOne, Inc. (BLLN)2025-12-31$57.23M+11.2%
Castle Biosciences Inc (CSTL)2025-12-31$10.06M+0.3%
Caris Life Sciences, Inc. (CAI)2025-12-31$378.45M+1.4%
Guardant Health, Inc. (GH)2025-12-31$1.50B+31.6%
RadNet, Inc. (RDNT)2025-12-31$1.09B+7.2%
Quest Diagnostics Inc (DGX)2025-12-31$5.67B-8.8%

Compare BDSX, XGN, AMS, BLLN side by side · Screen every company in Services-Medical Laboratories ↗